During the past decade, Centrum kardiovaskularni prevence 1. LF UK a TN conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centrum kardiovaskularni prevence 1. LF UK a TN" are "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Centrum kardiovaskularni prevence 1. LF UK a TN" in a lesser frequency.

Most popular intervention types in "Centrum kardiovaskularni prevence 1. LF UK a TN" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centrum kardiovaskularni prevence 1. LF UK a TN" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Centrum kardiovaskularni prevence 1. LF UK a TN". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Centrum kardiovaskularni prevence 1. LF UK a TN, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centrum kardiovaskularni prevence 1. LF UK a TN, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".